Trial Profile
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 13 Mar 2023 Status changed from active, no longer recruiting to completed.
- 09 Apr 2022 The trial has been completed in France, (Date of the global end of the trial : 16-02-2022), according to European Clinical Trials Database record.
- 05 Apr 2022 This trial has been completed in Netherland (Date of the global end of the trial : 25-May-2017), according to European Clinical Trials Database record.